Santok

What Santok does

STK (legal entity: Santok Group) is a UK-headquartered mobile device manufacturer that designs and builds purpose-built smartphones, tablets, and accessories for global clinical trials, with a particular focus on electronic Clinical Outcome Assessment (eCOA), electronic Patient-Reported Outcome (ePRO) workflows, and decentralised clinical trial (DCT) deployments. The company has been designing and manufacturing mobile devices since 1993, operating for over a decade in a white-label/ODM capacity for major carriers and brands before repositioning in 2026 under its own brand for the clinical research and life sciences market. Its flagship device portfolio comprises STK Helix (a next-generation 5G AI-native smartphone running Android 16), STK X3 (a proven clinical smartphone with 200,000+ units deployed globally), and the upcoming STK Tablet line, all supported by a single STK Global Charger with interchangeable regional plugs.

The technical platform layers proprietary capabilities on top of the hardware. STK Cortex™ is an on-device AI capability layer (with a public v1.1 through v1.4 roadmap covering biometric identity, multilingual ePRO across 500+ languages, passive gait/motion/sleep signal capture, voice workflows, and standardised imaging) that processes sensitive participant data locally. STK Nexus™ is a global connectivity platform delivering 4G/5G service via 500+ carriers across 200+ countries through physical or eSIM. Devices are AER/GMS certified and cleared in 89 markets, with a guaranteed 7-year lifecycle and 5-year warranty supporting the multi-year duration of clinical studies.

The business model combines one-time hardware sales (purpose-built smartphones and tablets) with recurring revenue streams from warranty and instant-replacement services, STK Nexus™ connectivity subscriptions, and professional services for device provisioning, kitting, and global fulfilment from the 30,000 sq. ft. UK warehouse and regional hubs across Europe, China, and the Middle East. Pricing is quote-based with multi-year contracts, and go-to-market is enterprise field sales — engineering-reviewed proposals with 24-hour response — targeting pharma sponsors, Contract Research Organisations (CROs), and life sciences technology providers such as Signant Health.

Name

Santok

Legal name

Santok Group

Website

https://stklife.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Short description

STK (Santok Group) is a UK mobile device manufacturer that designs purpose-built smartphones, tablets, and on-device AI software for pharma sponsors, CROs, and life sciences technology providers running global eCOA, ePRO, and decentralised clinical trials.

Ownership category

akta.pro rank

Product category

Clinical trial mobile devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Healthcare/Clinical Tablets (HDACAMAE)

akta.pro secondary industries

Rugged Tablets (Industrial/Field) (HDACAMAD), Rugged & Specialized Smartphones/Feature Phones (Industrial, Outdoor, Secure) (CRACALAJ)

Keywords

• Clinical trial devices
• ECOA smartphones
• EPRO data capture
• Decentralised clinical trials
• Purpose-built mobile devices

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Device Sales: Sale of purpose-built smartphones and tablets (STK Helix, STK X3, STK Tablet) to pharma companies, CROs, and clinical research organisations for provisioned device clinical trial programmes.
2. Warranty and Replacement Services: 5-year warranty with instant device replacement policy bundled with device purchases, protecting study continuity.
3. Global Connectivity Services: STK Nexus™ connectivity services providing 4G/5G data coverage via physical or eSIM across 500+ carriers in 200+ countries.
4. Device Provisioning and Kitting: Regional fulfilment services including device configuration, kitting, and rapid deployment to clinical trial sites worldwide from UK warehouse and regional hubs.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

STK designs and manufactures purpose-built smartphones and tablets specifically for global clinical trial deployment, targeting eCOA, ePRO, and decentralised clinical trial workflows. The offering combines proprietary hardware (STK Helix, STK X3, STK Tablet), the STK Cortex™ on-device AI capability layer, and STK Nexus™ global connectivity platform, all bundled with a 7-year lifecycle guarantee, 5-year warranty, and a single global charging solution. Devices are sold with provisioning, kitting, and global fulfilment services to pharma companies, CROs, and life sciences technology providers.

Product overview

STK (Santok) offers a platform-plus-modules architecture of purpose-built mobile devices for global clinical trials. The core hardware portfolio includes STK Helix (next-generation 5G AI-native smartphone), STK X3 (proven clinical smartphone with 200K+ deployments), and STK Tablet (upcoming site-based eCOA device). All devices share the STK Cortex™ on-device AI layer and STK Nexus™ global connectivity platform, and ship with the STK Global Charger as standard. The integrated platform provides 7-year lifecycle support, Android 16 OS, global certification in 80+ countries, and AI-enabled features including biometric identity, multilingual ePRO, and passive signal capture.

Differentiator

Problem solved

Functional benefit

Brands

• STK Cortex™: On-device AI capability layer for STK devices, supporting biometric identity, multilingual ePRO engagement, and passive signal capture for clinical research workflows.
• STK Nexus™
• STK Helix
• STK X3
• STK Tablet
• STK Global Charger

Products and services

• STK Helix Next-generation eCOA and ePRO smartphone purpose-built for decentralised clinical trials. Combines Android 16, on-device STK Cortex™ AI, and Global 5G connectivity via STK Nexus™ with a 7-year clinical trial lifecycle and 5-year warranty. Designed for pharma companies, CROs, and life sciences technology providers running multinational clinical studies.
• STK X3 Proven clinical smartphone with 200,000+ deployments across global clinical trials. Features durable modern design, removable battery, globally certified, and bundled with a 5-year warranty. Designed for patient-reported outcome workflows with single-SKU global deployment and multi-year clinical studies.
• STK Tablet Larger format Android AI-enabled tablet for site-based eCOA workflows. Available in 11" and 13" formats, engineered to the same platform, lifecycle, and connectivity standards as STK Helix and X3. Designed for clinical trial sites needing larger screen real estate for eCOA data capture.
• STK Global Charger Single global charging solution included with every STK device. Compact USB-C power brick with interchangeable regional plugs (UK, EU, US, AU, India, China) reducing inventory complexity across international trials. Fully certified for clinical deployment in each target country.
• Device Provisioning and Kitting Services Regional fulfilment services including device configuration, kitting, and rapid deployment to clinical trial sites worldwide from a 30,000 sq. ft. UK warehouse and regional hubs across Europe, China, and the Middle East. Sold alongside STK device purchases.

Quantifiable outcome

• 200,000+ devices deployed across clinical environments
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Google (Android Enterprise)coreTechnology or IntegrationSTK devices are Android Enterprise Recommended (AER) and Google Mobile Services (GMS) certified, guaranteeing Google compliance, 100% security, zero-touch provisioning, and Android update readiness.
• Global Mobile Carriers (500+)coreTechnology or IntegrationSTK Nexus™ connectivity platform enables devices to operate across 500+ global carriers in 200+ countries via physical SIM or eSIM, providing uninterrupted global data coverage for clinical trials.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Signant Health: Leading eCOA/ePRO platform provider and named STK enterprise customer. Signant operates the SmartSignals eCOA software that runs on STK X3 devices, making it both a channel partner and a broader incumbent whose platform decisions shape STK's demand.
• Clario: Large clinical trial technology company offering eCOA, imaging and endpoint solutions, often bundling provisioned devices into eCOA programmes. Competes for the same pharma and CRO budgets as STK but as part of a much wider technology portfolio.
• Medidata (Dassault Systèmes): Operates the Rave eCOA platform used across many global trials and supports BYOD and provisioned device strategies. Competes head-to-head with STK's target customers (pharma sponsors and CROs) as a broad clinical trial platform incumbent.
• YPrime: eCOA and clinical trial technology provider serving pharma and CRO customers with configurable device strategies. Comparable to STK at the buyer level and a potential partner or competitor depending on the sponsor's device sourcing decision.
• IQVIA: Global CRO and clinical technology provider with eCOA, decentralised trial and patient engagement capabilities. Engages the same pharma and CRO buyers as STK and can act as both a potential channel and a competitive bundler.
• Samsung Electronics: Global smartphone and tablet maker with Knox enterprise security and Android Enterprise Recommended devices used in some clinical research deployments. Represents the consumer-grade alternative and potential competitor should sponsors prefer off-the-shelf enterprise devices over STK's purpose-built SKUs.
• Apple: Consumer smartphone and wearable maker whose ResearchKit and clinical research partnerships underpin much of the BYOD trend in trials. A structural competitor to purpose-built device makers like STK, as its installed base enables app-only eCOA without provisioned hardware.

Emerging players

• ActiGraph: Manufacturer of clinical-grade wearable activity monitors widely used as digital endpoints in clinical trials. Comparable to STK as a purpose-built hardware vendor for clinical research, but focused on wearable sensors rather than smartphones and tablets.
• Empatica: Developer of clinical-grade wearables (e.g., EpiMonitor, Embrace) used in decentralised and remote clinical trials for passive data capture. Comparable in purpose-built clinical hardware positioning and overlap with STK Cortex's passive signal roadmap.
• Biofourmis: Remote patient monitoring and decentralised clinical trial platform combining software with connected biosensors. Competes with STK in DCT programmes and addresses overlapping use cases (passive monitoring, home-based trials).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/stkaccessories
• Facebookfacebook.com/stklife
• LinkedInlinkedin.com/company/stk

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santok